Research ExplorerPublicationsCytoreductive surgery of glioblastoma as the key to successf...

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.

Standard

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. / Stummer, Walter; Bent, van den; Westphal, Manfred; Westphal, Manfred.

In: ACTA NEUROCHIR, Vol. 153, No. 6, 6, 2011, p. 1211-1218.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stummer, W, Bent, VD, Westphal, M & Westphal, M 2011, 'Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.', ACTA NEUROCHIR, vol. 153, no. 6, 6, pp. 1211-1218. <http://www.ncbi.nlm.nih.gov/pubmed/21479583?dopt=Citation>

APA

Stummer, W., Bent, V. D., Westphal, M., & Westphal, M. (2011). Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. ACTA NEUROCHIR, 153(6), 1211-1218. [6]. http://www.ncbi.nlm.nih.gov/pubmed/21479583?dopt=Citation

Vancouver

Stummer W, Bent VD, Westphal M, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. ACTA NEUROCHIR. 2011;153(6):1211-1218. 6.

Bibtex

@article{cbc4db344cf2489490752fd7203a6929,
title = "Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.",
abstract = "This article discusses data from 3 randomized phase 3 trials, supporting a role for surgery in glioblastoma.",
keywords = "Humans, Male, Aged, Female, Middle Aged, Randomized Controlled Trials as Topic, Prognosis, Survival Rate, Follow-Up Studies, Combined Modality Therapy, Proportional Hazards Models, Dose Fractionation, Chemotherapy, Adjuvant, Cranial Irradiation, Radiotherapy, Adjuvant, Antineoplastic Agents, Alkylating/administration & dosage, Brain Neoplasms/*drug therapy/mortality/*radiotherapy/*surgery, Carmustine/administration & dosage, Dacarbazine/administration & dosage/analogs & derivatives, Glioblastoma/*drug therapy/mortality/*radiotherapy/*surgery, Humans, Male, Aged, Female, Middle Aged, Randomized Controlled Trials as Topic, Prognosis, Survival Rate, Follow-Up Studies, Combined Modality Therapy, Proportional Hazards Models, Dose Fractionation, Chemotherapy, Adjuvant, Cranial Irradiation, Radiotherapy, Adjuvant, Antineoplastic Agents, Alkylating/administration & dosage, Brain Neoplasms/*drug therapy/mortality/*radiotherapy/*surgery, Carmustine/administration & dosage, Dacarbazine/administration & dosage/analogs & derivatives, Glioblastoma/*drug therapy/mortality/*radiotherapy/*surgery",
author = "Walter Stummer and Bent, {van den} and Manfred Westphal and Manfred Westphal",
year = "2011",
language = "English",
volume = "153",
pages = "1211--1218",
journal = "ACTA NEUROCHIR",
issn = "0001-6268",
publisher = "Springer Wien",
number = "6",

}

RIS

TY - JOUR

T1 - Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.

AU - Stummer, Walter

AU - Bent, van den

AU - Westphal, Manfred

AU - Westphal, Manfred

PY - 2011

Y1 - 2011

N2 - This article discusses data from 3 randomized phase 3 trials, supporting a role for surgery in glioblastoma.

AB - This article discusses data from 3 randomized phase 3 trials, supporting a role for surgery in glioblastoma.

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Prognosis

KW - Survival Rate

KW - Follow-Up Studies

KW - Combined Modality Therapy

KW - Proportional Hazards Models

KW - Dose Fractionation

KW - Chemotherapy, Adjuvant

KW - Cranial Irradiation

KW - Radiotherapy, Adjuvant

KW - Antineoplastic Agents, Alkylating/administration & dosage

KW - Brain Neoplasms/drug therapy/mortality/radiotherapy/surgery

KW - Carmustine/administration & dosage

KW - Dacarbazine/administration & dosage/analogs & derivatives

KW - Glioblastoma/drug therapy/mortality/radiotherapy/surgery

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Prognosis

KW - Survival Rate

KW - Follow-Up Studies

KW - Combined Modality Therapy

KW - Proportional Hazards Models

KW - Dose Fractionation

KW - Chemotherapy, Adjuvant

KW - Cranial Irradiation

KW - Radiotherapy, Adjuvant

KW - Antineoplastic Agents, Alkylating/administration & dosage

KW - Brain Neoplasms/drug therapy/mortality/radiotherapy/surgery

KW - Carmustine/administration & dosage

KW - Dacarbazine/administration & dosage/analogs & derivatives

KW - Glioblastoma/drug therapy/mortality/radiotherapy/surgery

M3 - SCORING: Journal article

VL - 153

SP - 1211

EP - 1218

JO - ACTA NEUROCHIR

JF - ACTA NEUROCHIR

SN - 0001-6268

IS - 6

M1 - 6

ER -